- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tumor cell response to bevacizumab single agent therapy in vitro ; volume:13 ; number:1 ; day:23 ; month:9 ; year:2013 ; pages:1-11 ; date:12.2013
Cancer cell international ; 13, Heft 1 (23.9.2013), 1-11, 12.2013
- Urheber
-
Hein, Melanie
- Beteiligte Personen und Organisationen
-
Graver, Shannon
SpringerLink (Online service)
- DOI
-
10.1186/1475-2867-13-94
- URN
-
urn:nbn:de:1111-2016073021068
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hein, Melanie
- Graver, Shannon
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tumor cell response to bevacizumab single agent therapy in vitro
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Addition of anti-angiogenetic therapy with bevacizumab to chemo- and radiotherapy for leptomeningeal metastases in primary brain tumors
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy
In vitro effects of Bevacizumab and Sunitinib in human alveolar osteoblasts
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report
Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Tumor cell response to bevacizumab single agent therapy in vitro
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Addition of anti-angiogenetic therapy with bevacizumab to chemo- and radiotherapy for leptomeningeal metastases in primary brain tumors
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy
In vitro effects of Bevacizumab and Sunitinib in human alveolar osteoblasts
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report
Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Tumor cell response to bevacizumab single agent therapy in vitro
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Addition of anti-angiogenetic therapy with bevacizumab to chemo- and radiotherapy for leptomeningeal metastases in primary brain tumors
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy
In vitro effects of Bevacizumab and Sunitinib in human alveolar osteoblasts
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report
Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report